FDA Delays Approval of Moderna Vaccine for Adolescent Vaccination

In a weekend statement, Moderna stated that the US FDA needs more time to evaluate the international analysis of rare myocarditis caused by the vaccine, which means that the regulator may not be able to approve the vaccine for use within the year. Youth vaccination. Affected by this news, the company's stock price fell nearly 7% after the opening on Monday, but then continued to rise, closing the day with a drop of 2.33%.

$Moderna(MRNA.US)$

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

举报

评论

  • 推荐
  • 最新
empty
暂无评论